Incontinentia pigmenti: a rare cause of skin rash in newborn
DOI:
https://doi.org/10.18203/2349-3291.ijcp20243096Keywords:
Incontinentia pigmenti, NEMO gene, Skin rashAbstract
Incontinentia pigmenti (IP) is a genodermatosis caused by mutations in the NEMO gene (Xq28) and is lethal in males. It is an X-linked dominant disorder with multi-systemic involvement. It involves the central nervous system and ectodermal tissues like skin, teeth, hair, nails, eyes, and the commonest manifestations are cutaneous manifestations. Here we present a case of a female newborn with vesico bullous eruption presented at birth. A full-term newborn female patient born by LSCS presented at birth with multiple vesico bullous skin lesions over bilateral upper and lower limbs in a pattern consistent with Blaschko's lines. Maternal HIV, HBsAg, VDRL, and TORCH screening were negative. Systemic examinations were normal. Supportive care and IV antibiotics with IV acyclovir were started but without any response. The sepsis screen, blood, and urine culture were negative. ANA was negative. Wound swab culture and skin culture were negative. Skin biopsy results showed eosinophilic infiltration of the dermis and spongiosis. Genetic testing could not be done. Topical steroids were prescribed. The diagnosis of Incontinentia pigmenti was established based on the patient's skin lesions and biopsy results. The baby improved and was discharged on the 14th day of life on topical steroids and is currently under follow-up. Other dermatologic conditions, like mastocytosis and hereditary epidermolysis bullosa, should be considered in the differential diagnosis of Incontinentia pigmenti. The diagnosis of Incontinentia pigmenti should be confirmed by histopathological examination of biopsy specimens along with genetic testing. It is a systemic disorder, so clinical management should include a multidisciplinary approach.
Metrics
References
Winterberg DH, Van Tijn DA, Smitt JH, Winterberg S, Vomberg PP: Two neonates with vesicular skin lesions due to incontinentia pigmenti. Ned Tijdschr Geneedsk. 2001;145:2178-82.
Bodemer C, Diociaiuti A, Hadj-Rabia S. Multidisciplinary consensus recommendations from a European network for the diagnosis and practical management of patients with incontinentia pigmenti. J Eur Acad Dermatol Venereol. 2020;34:1415-24.
Wright JT, Fete M, Schneider H. Ectodermal dysplasias: classification and organization by phenotype, genotype and molecular pathway. Am J Med Genet A. 2019;179:442-7.
Hadj-Rabia S, Froidevaux D, Bodak N. Clinical study of 40 cases of Incontinentia pigmenti. Arch Dermatol. 2003;139:1163-70.
Fusco F, Conte MI, Diociaiuti A. Unusual father-to-daughter transmission of Incontinentia pigmenti due to mosaicism in IP males. Pediatrics. 2017;140(10):1542.
Cai YR, Liang Y, Zhong X. Late contralateral recurrence of retinal detachment in Incontinentia pigmenti: a case report. World J Clin Cases. 2022;10:4171-6.
Dupati A, Egbers RG, Helfrich YR. A case of Incontinentia pigmenti reactivation after 12-month immunizations. JAAD Case Reports. 2015;1:351-2.
Hoath SB. Vivek Nrendran: The skin of the neonate. Philadelphia: Walsh Neonatal-Perinatal Medicine. 2015;1715:7.
Swinney CC, Han DP, Karth PA. Incontinentia pigmenti: a comprehensive review and update. Ophthalmic Surg Lasers Imaging Retina. 2015;46:650-7.
Kawai M, Sugimoto A, Ishihara Y, Kato T, Kurahashi H. Incontinentia pigmenti inherited from a father with a low level atypical IKBKG deletion mosaicism: a case report. BMC Pediatr. 2022;22:378.
How KN, Leong HJY, Pramono ZAD, Leong KF, Lai ZW, Yap WH. Uncovering incontinentia pigmenti: from DNA sequence to pathophysiology. Front Pediatr. 2022;10:900606.
Fusco F, Pescatore A, Steffann J. Clinical utility gene card for incontinentia pigmenti. Eur J Hum Genet. 2019;27:1894-900.
Li WC, Li ML, Ding JW. Incontinentia pigmenti with intracranial arachnoid cyst: a case report. World J Clin Cases. 2022;10:8352-9.
Liang L, Yang Y, Bu S, Lu F. Case report: a case of cotton-wool spots after intravitreal injection of conbercept in an infant with incontinentia pigmenti. Front Med. 2021;8:761398.
Ni Y, Huang X, Ruan L. Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti. J AAPOS. 2018;22(4):325-7.
Hsieh DT, Chang T: Incontinentia pigmenti: skin and magnetic resonance imaging findings. Arch Neurol. 2011, 68:1080. 10.1001/archneurol.2011.164
Soltirovska Salamon A, Lichtenbelt K, Cowan FM. Clinical presentation and spectrum of neuroimaging findings in newborn infants with incontinentia pigmenti. Dev Med Child Neurol. 2016;58:1076-84.
Huang SY, Chen LJ, Chiu SC: A 7-year-old female child of incontinentia pigmenti presenting with vitreous hemorrhage. Indian J Ophthalmol. 2017;65:533-5.
O’Doherty M, Mc Creepy K, Green AJ, Tuwir I, Brosnahan D: Incontinentia pigmenti--ophthalmological observation of a series of cases and review of the literature. Br J Ophthalmol. 2011;95:11-6.
Poziomczyk CS, Recuero JK, Bringhenti L, et al.: Incontinentia pigmenti. An Bras Dermatol. 2014;89:26-36.
Islam YFK, Khurshid SG: Incontinentia pigmenti and the eye. Curr Opin Ophthalmol. 2022;33:525-31.
Minic S, Trpinac D, Obradovic M: Incontinentia pigmenti diagnostic criteria update. Clin Genet. 2014;85:536-42.
Fusco F, Paciolla M, Conte MI. Incontinentia pigmenti: report on data from 2000 to 2013. Orphanet J Rare Dis. 2014;9:93.